Accessibility Menu
Sernova Biotherapeutics logo

Sernova Biotherapeutics(TSX) SVA

Market CapCA$41.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2000)-97%
5 Year-92%
1 Year-44%
1 Month-4%
CA$0.11
+0.00%
+0.00Today
Sernova Biotherapeutics last closing stock price
MetricPriceDate
Last closeCAD 0.112026-08-14
Sernova Biotherapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.35%CAD 0.122026-08-07
1 month-4.35%CAD 0.122026-07-15
3 month-29.03%CAD 0.162026-05-15
Year to date-15.38%CAD 0.132025-12-31
1 year-43.59%CAD 0.202025-08-14
3 year-86.75%CAD 0.832023-08-15
5 year-91.67%CAD 1.322021-08-13
Since inception-96.94%CAD 3.602000-02-29

Sernova Biotherapeutics Financials at a Glance

Market Cap

CA$41.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$11.83M

EPS (TTM)

-CA$0.04

P/E Ratio

-3.13

Dividend

CA$0.00

Beta (Volatility)

0.49 (Low)

Price

CA$0.11

Volume

5,147

Open

CA$0.11

Previous Close

CA$0.11

Daily Range

CA$0.11 - CA$0.12

52-Week Range

CA$0.11 - CA$0.20

Estimated Earnings Date

Sep 10, 2026

SVA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Sernova Biotherapeutics

Sernova Corp. is a Canadian clinical-stage biotechnology company focused on developing innovative regenerative medicine therapies. The company specializes in its proprietary Cell Pouch system, designed to enhance the transplantation and engraftment of therapeutic cells for chronic conditions.

Products and Services
  • Cell Pouch system for localized cellular immune protection
  • Therapeutic cells for chronic conditions like diabetes and hemophilia
  • Collaborative research with AgeX Therapeutics and the University of Miami
Growth Outlook
  • Partnerships with leading research institutions enhance product development
  • Focus on chronic conditions presents significant market opportunities
  • Innovative technology positions Sernova for future advancements in regenerative medicine
Financial Highlights
  • Recent quarterly net income of -3.23 million CAD reflects ongoing R&D investments
  • Cash and cash equivalents increased to 1.05 million CAD in Q2 2026
  • Market capitalization stands at approximately 41.54 million CAD
Sernova Corp. operates in a promising sector, leveraging its unique technology to address significant medical needs. The company's focus on research and development, coupled with strategic partnerships, positions it well for future growth. Recent financial data indicates a commitment to innovation, although the company continues to operate at a loss as it invests heavily in its product pipeline. The increase in cash reserves suggests a stable financial footing to support ongoing projects. Overall, Sernova Corp. represents an intriguing opportunity within the biotechnology landscape.
AI Generated • Aug 1, 2026

Industry

Biotechnology

Sector

Health Care

Employees

8

CEO

Jonathan M. N. Rigby, MBA

Website

www.sernova.com

Headquarters

Mississauga, ON L5A 4H2, CA

SVA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

55.85%

Return on Capital

N/A

Return on Assets

-771.32%

Earnings Yield

-31.95%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$41.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

377.64M

Volume

5.15K

Avg. Volume

120.68K

Financials (TTM)

Gross Profit

-CA$256.13K

Operating Income

-CA$10.28M

EBITDA

-CA$10.22M

Operating Cash Flow

-CA$5.50M

Capital Expenditure

-CA$4.00

Free Cash Flow

-CA$5.50M

Cash & ST Invst.

CA$1.05M

Total Debt

CA$2.45M

Sernova Biotherapeutics Performance Analysis

Sernova Biotherapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-10-31CAD 0N/A
20232023-10-31CAD 0N/A
20242024-10-31CAD 0N/A
20252025-10-31CAD 0N/A
Sernova Biotherapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-07-31N/A
Q42025-10-31N/A
Q12026-01-31N/A
Q22026-04-30N/A
Sernova Biotherapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-10-31CAD -0.09214.4%
20232023-10-31CAD -0.1344.0%
20242024-10-31CAD -0.10-18.4%
20252025-10-31CAD -0.05-54.2%
Sernova Biotherapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-07-31-7.8%
Q42025-10-3146.8%
Q12026-01-31-4.5%
Q22026-04-30-33.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

-CA$4.43K

+90.7%

Gross Margin

0.00%

N/A

Market Cap

CA$41.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$5.19M

N/A

Employees

8

N/A

Net Income

-CA$3.23M

+14.5%

EBITDA

-CA$2.30M

+33.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CA$1.05M

-47.3%

Total Debt

CA$2.45M

-48.2%

Accounts Receivable

CA$116.84K

-73.0%

Inventory

CA$0.00

N/A

Long Term Debt

CA$229.24K

-81.2%

Short Term Debt

CA$2.22M

-36.8%

Return on Assets

-7.71%

N/A

Return on Invested Capital

1.09%

N/A

Free Cash Flow

-CA$2.21M

+42.5%

Operating Cash Flow

-CA$2.21M

+42.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MBX.TOMicrobix Biosystems Inc.
CA$0.30+0.00%
BCT.TOBriaCell Therapeutics Corp.
CA$4.74-1.25%
MIR.VMedMira Inc.
CA$0.06+0.00%
RVX.TOResverlogix Corp.
CA$0.11+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About SVA

What is the current price of Sernova Biotherapeutics?

Sernova Biotherapeutics is trading at CA$0.11 per share.

What is the 52-week range for Sernova Biotherapeutics?

Over the past 52 weeks, Sernova Biotherapeutics has traded between CA$0.11 and CA$0.20.

How much debt does Sernova Biotherapeutics have?

As of the most recent reporting period, Sernova Biotherapeutics reported total debt of CA$2.45M.

How much cash does Sernova Biotherapeutics have on hand?

Sernova Biotherapeutics reported CA$1.05M in cash and cash equivalents in its most recent financial results.

What is Sernova Biotherapeutics’s dividend yield?

Sernova Biotherapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services